-
Jude Medical (nyse: STJ - news - people ) of St.
FORBES: J&J Walks Away
-
Jude Medical Inc. ( STJ), State Street Corp. ( STT) and Citigroup ( C).
FORBES: Sarah Ketterer Gains 24 Pct in 2012 - Her Top Q4 Buys
-
Shares of STJ are down about 13% over the past year, but have gained 30% since early November.
FORBES: Magazine Article
-
Jude Medical ( STJ), a company that YCharts Pro says is significantly underpriced.
FORBES: St. Jude's Emerges From Shadow Of Health Care Reform
-
Other competitors in the healthcare sector include: Medtronic (MDT), St Jude Medical (STJ), and Boston Scientific (BSX).
FORBES: Earnings Preview: Edwards Lifesciences
-
Jude Medical (nyse: STJ - news - people ).
FORBES: On The Cover/Top Stories
-
Jude Medical ( STJ - news - people ).
FORBES: On The Cover/Top Stories
-
Jude Medical (STJ) is hoping its third quarter earnings report on Wednesday, October 17, 2012 will help continue the momentum its stock price has enjoyed.
FORBES: Earnings Preview: St. Jude Medical
-
Jude Medical (nyse: STJ - news - people ) failed because of susceptibility of a component to damage caused by cosmic rays.
FORBES: All In!
-
Jude Medical (nyse: STJ - news - people ), a smaller maker of defibrillators and pacemakers that he feels has been constrained by a too-tiny sales force.
FORBES: JNJ-Guidant Vs. Boston-Scientific-St. Jude
-
Jude Medical ( STJ).
FORBES: Money Where Your Mouth Is
-
Jude Medical (nyse: STJ - news - people ), adult education outfit Apollo Group (nasdaq: APOL - news - people ), network security company Symantec (nasdaq: SYMC - news - people ) and eBay (nasdaq: EBAY - news - people ).
FORBES: Magazine Article
-
Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced today that an interim analysis of the FAME II trial has found a highly statistically significant reduction in the need for hospital readmission and urgent revascularization when Fractional Flow Reserve (FFR)-guided assessment was used to direct treatment in patients with coronary artery disease.
FORBES: New Enrollment in FAME II Halted After Interim Analysis Shows Benefits of FFR